Literature DB >> 23540483

Influence of chronic comorbidity and medication on the efficacy of treatment in patients with diabetes in general practice.

Welcome Mkululi Wami1, Frank Buntinx, Stefaan Bartholomeeusen, Geert Goderis, Chantal Mathieu, Marc Aerts.   

Abstract

BACKGROUND: Evidence on the influence of comorbidity and comedication on clinical outcomes in patients with type 2 diabetes mellitus is scarce. AIM: To ascertain the effect of five chronic diseases (joint disorder, respiratory disease, anaemia, malignancy, depression) and three chronically used drugs (non-steroid anti-inflammatory drugs [NSAIDs], corticosteroids, antidepressants) on treatment for hypoglycaemia in patients with type 2 diabetes. DESIGN AND
SETTING: Retrospective cohort study in a variety of practices across Flanders, Belgium.
METHOD: A retrospective cohort study was conducted, based on data from Intego, a general practice-based continuous morbidity registry. Multiple logistic regression analysis was used to predict the change in glycosylated haemoglobin (HbA1c) levels related to comorbidity, comedication, and a combination of both in 3416 patients with type 2 diabetes. Adjustments were made for age, sex, and diabetes-treatment group (diet, oral antidiabetic drugs, combination treatment, insulin).
RESULTS: Concomitant joint and respiratory disorders, as well as the chronic use of NSAIDs and corticosteroids, either separately or in combination, were significantly associated with the worsening of HbA1c levels. Anaemia, depression, malignancy, and antidepressants had no statistically significant influence on the efficacy of treatment for hypoglycaemia.
CONCLUSION: The presence of some comorbid diseases or drug use can impede the efficacy of treatment for type 2 diabetes. This finding supports the need to develop treatment recommendations, taking into account the presence of both chronic comorbidity and comedication. Further research must be undertaken to ascertain the effect other combinations of chronic diseases have on the efficacy of treatment of this and other diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23540483      PMCID: PMC3609474          DOI: 10.3399/bjgp13X665233

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  28 in total

Review 1.  Standards of medical care in diabetes--2012.

Authors: 
Journal:  Diabetes Care       Date:  2012-01       Impact factor: 19.112

2.  Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  S E Inzucchi; R M Bergenstal; J B Buse; M Diamant; E Ferrannini; M Nauck; A L Peters; A Tsapas; R Wender; D R Matthews
Journal:  Diabetologia       Date:  2012-04-20       Impact factor: 10.122

Review 3.  Rheumatic manifestations of diabetes mellitus.

Authors:  Dorota Lebiedz-Odrobina; Jonathan Kay
Journal:  Rheum Dis Clin North Am       Date:  2010-11       Impact factor: 2.670

4.  Comorbidity and guidelines: conflicting interests.

Authors:  Chris van Weel; François G Schellevis
Journal:  Lancet       Date:  2006-02-18       Impact factor: 79.321

5.  Adapting clinical guidelines to take account of multimorbidity.

Authors:  Bruce Guthrie; Katherine Payne; Phil Alderson; Marion E T McMurdo; Stewart W Mercer
Journal:  BMJ       Date:  2012-10-04

6.  Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.

Authors:  Joseph Menzin; Jonathan R Korn; Joseph Cohen; Francis Lobo; Bin Zhang; Mark Friedman; Peter J Neumann
Journal:  J Manag Care Pharm       Date:  2010-05

7.  Association between glycemic state and lung function: the Framingham Heart Study.

Authors:  Robert E Walter; Alexa Beiser; Rachel J Givelber; George T O'Connor; Daniel J Gottlieb
Journal:  Am J Respir Crit Care Med       Date:  2003-03-15       Impact factor: 21.405

8.  Effects of enhanced depression treatment on diabetes self-care.

Authors:  Elizabeth H B Lin; Wayne Katon; Carolyn Rutter; Greg E Simon; Evette J Ludman; Michael Von Korff; Bessie Young; Malia Oliver; Paul C Ciechanowski; Leslie Kinder; Edward Walker
Journal:  Ann Fam Med       Date:  2006 Jan-Feb       Impact factor: 5.166

9.  Comorbid conditions and glycemic control in elderly patients with type 2 diabetes mellitus, 1988 to 1994 to 1999 to 2004.

Authors:  Dong-Churl Suh; Chul-Min Kim; In-Sun Choi; Craig A Plauschinat
Journal:  J Am Geriatr Soc       Date:  2008-01-02       Impact factor: 5.562

Review 10.  Musculoskeletal manifestations of diabetes mellitus.

Authors:  L L Smith; S P Burnet; J D McNeil
Journal:  Br J Sports Med       Date:  2003-02       Impact factor: 13.800

View more
  7 in total

1.  Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data.

Authors:  Michael J Davies; Katherine Merton; Ujjwala Vijapurkar; Jacqueline Yee; Rong Qiu
Journal:  Cardiovasc Diabetol       Date:  2017-03-21       Impact factor: 9.951

Review 2.  Clinical drug trials in general practice: how well are external validity issues reported?

Authors:  Anja Maria Brænd; Jørund Straand; Atle Klovning
Journal:  BMC Fam Pract       Date:  2017-12-29       Impact factor: 2.497

3.  Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective U.S. database.

Authors:  Steven R Feldman; Haijun Tian; Isabelle Gilloteau; Patrick Mollon; Meng Shu
Journal:  BMC Health Serv Res       Date:  2017-05-08       Impact factor: 2.655

4.  Evaluating quality of overall care among older adults with diabetes with comorbidities in Ontario, Canada: a retrospective cohort study.

Authors:  Yelena Petrosyan; Kerry Kuluski; Jan Barnsley; Barbara Liu; Walter P Wodchis
Journal:  BMJ Open       Date:  2020-02-06       Impact factor: 2.692

5.  Effective Overall Glycaemic Control with Fast-Acting Insulin Aspart Across Patients with Different Baseline Characteristics: A Post Hoc Analysis of the Onset 9 Trial.

Authors:  Wendy Lane; Elena Favaro; Esteban Jódar; Pranav Kelkar; Alejandra Oviedo; Ramsathish Sivarathinasami; Peter A Senior; Giorgio Sesti; Edward Franek
Journal:  Diabetes Ther       Date:  2022-03-15       Impact factor: 2.945

6.  Role of Tiotropium in Reducing Exacerbations of Chronic Obstructive Pulmonary Disease When Combined With Long-Acting β2 -Agonists and Inhaled Corticosteroids: The OUTPUL Study.

Authors:  Eliana Ferroni; Valeria Belleudi; Silvia Cascini; Mirko Di Martino; Ursula Kirchmayer; Riccardo Pistelli; Elisabetta Patorno; Giulio Formoso; Danilo Fusco; Carlo A Perucci; Marina Davoli; Nera Agabiti
Journal:  J Clin Pharmacol       Date:  2016-11       Impact factor: 3.126

Review 7.  A Metabolomics Approach to Pharmacotherapy Personalization.

Authors:  Elena E Balashova; Dmitry L Maslov; Petr G Lokhov
Journal:  J Pers Med       Date:  2018-09-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.